Novo Nordisk targets a ~2030 launch for UBT251, a triple-G obesity drug showing up to 19.7% weight loss in a China Phase 2.
The molecules known as triple-Gs — agonists of GLP-1, GIP and glucagon — are drawing attention as data build suggesting they could be the most effective class …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone
Monthly GLP-1 for Obesity Promising as More Manageable Alternative
Novo Nordisk CEO looks beyond weight loss to longevity and aesthetics | Fortune
Novo Nordisk CEO Hints Semaglutide Could Be More Than Weight-Loss Drug - Novo Nordisk (NYSE:NVO)
Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes
Novo Nordisk released new data to underscore its pill's safety and effectiveness, while Trump is asked whether private plans…
The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around…
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
CNBC spoke with five U.S. patients who recently started the pill following its launch and have varying initial experiences with…
Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for…
The approval gives Novo Nordisk a head start over chief rival Eli Lilly, which is racing to launch its own obesity pill.
